GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (STU:XMP0) » Definitions » Shiller PE Ratio

Plus Therapeutics (STU:XMP0) Shiller PE Ratio : (As of May. 05, 2025)


View and export this data going back to . Start your Free Trial

What is Plus Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Plus Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Plus Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Shiller PE Ratio Chart

Plus Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Plus Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Plus Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Plus Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Shiller PE Ratio falls into.


;
;

Plus Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Plus Therapeutics's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Plus Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.64/133.1571*133.1571
=-0.640

Current CPI (Dec. 2024) = 133.1571.

Plus Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -19,624.372 99.621 -26,230.633
201506 3,007.125 100.684 3,977.002
201509 1,002.375 100.392 1,329.528
201512 -1,966.610 99.792 -2,624.129
201603 -2,761.350 100.470 -3,659.718
201606 -2,870.250 101.688 -3,758.495
201609 -1,737.450 101.861 -2,271.270
201612 -1,706.400 101.863 -2,230.643
201703 -2,314.125 102.862 -2,995.679
201706 -1,294.950 103.349 -1,668.440
201709 -874.657 104.136 -1,118.415
201712 -1,273.837 104.011 -1,630.792
201803 -444.022 105.290 -561.544
201806 -378.780 106.317 -474.405
201809 -355.184 106.507 -444.059
201812 -99.400 105.998 -124.869
201903 -118.413 107.251 -147.016
201906 -274.394 108.070 -338.093
201909 -0.409 108.329 -0.503
201912 3.075 108.420 3.777
202003 -3.801 108.902 -4.648
202006 -5.994 108.767 -7.338
202009 -4.967 109.815 -6.023
202012 -9.001 109.897 -10.906
202103 -4.158 111.754 -4.954
202106 -3.113 114.631 -3.616
202109 -3.570 115.734 -4.107
202112 -3.584 117.630 -4.057
202203 -2.588 121.301 -2.841
202206 -3.368 125.017 -3.587
202209 -2.879 125.227 -3.061
202212 -2.228 125.222 -2.369
202303 -1.933 127.348 -2.021
202306 -0.545 128.729 -0.564
202309 -0.937 129.860 -0.961
202312 -0.642 129.419 -0.661
202403 -0.690 131.776 -0.697
202406 -0.660 132.554 -0.663
202409 -0.333 133.029 -0.333
202412 -0.640 133.157 -0.640

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Plus Therapeutics  (STU:XMP0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Plus Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Plus Therapeutics Business Description

Traded in Other Exchanges
Address
2710 Reed Road, Suite 160, Houston, TX, USA, 77051
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Plus Therapeutics Headlines

No Headlines